DebbiePHaginsMD

PubMed

• 1 citations
  Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the ...
  Eva Fernvik, Juan Sierra Madero, Nuria Espinosa, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, ...> ;Journal of Acquired Immune Deficiency Syndromes. 2023 Nov 1
• 6 citations
  High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
  Paul E Sax, Kristen Andreatta, Jean-Michel Molina, Eric S Daar, Debbie Hagins, Rima Acosta, Michelle L D'Antoni, Silvia Chang, Ross Martin, Hui Liu, Christiana Blair, ...> ;AIDS. 2022 Sep 1
• 3 citations
  Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEM...
  Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian ...> ;HIV Research & Clinical Practice. 2021 Dec 9
• 11 citations
  Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
  Debbie Hagins, Princy Kumar, Michael S. Saag, Anson K Wurapa, Indira Brar, Daniel S Berger, Olayemi Osiyemi, Corrilynn O. Hileman, Moti Ramgopal, Cheryl McDonald, Chri...> ;Journal of Acquired Immune Deficiency Syndromes. 2021 Sep 1
• 3 citations
  Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
  Sarah-Jane Anderson, Miranda Murray, David Cella, Robert M. Grossberg, Debbie Hagins, William J. Towner, Marcia Wang, Andrew Clark, Amy Pierce, Cyril Llamoso, Peter Ac...> ;The Patient. 2021 Jun 28
• 47 citations
  Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144...
  Chloe Orkin, Edwin DeJesus, Paul E. Sax, Jose R. Arribas, Samir K. Gupta, Claudia Martorell, Jeffrey L. Stephens, Hans-Jürgen Stellbrink, David A. Wohl, Franco Maggiol...> ;The Lancet. HIV. 2020 Jun 1
• 19 citations
  Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
  Scott Letendre, Anthony Mills, Debbie Hagins, Susan Swindells, Franco Felizarta, Jerome deVente, Christopher J Bettacchi, Yu Lou, Susan L. Ford, Kenneth Sutton, Jafar ...> ;The Journal of Antimicrobial Chemotherapy. 2020 Mar 1
• 31 citations
  Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Mul...
  Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Je...> ;Journal of Acquired Immune Deficiency Syndromes. 2019 Nov 1
• 19 citations
  Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
  José M. Gatell, Javier O Morales-Ramirez, Debbie Hagins, Melanie A. Thompson, Keikawus Arastéh, Christian Hoffmann, François Raffi, Olayemi Osiyemi, Robin Dretler, Cha...> ;Antiviral Therapy. 2019 Jan 1
• 85 citations
  Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 resul...
  David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie A. Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei, Ri...> ;The Lancet. HIV. 2019 Jun 1
• 13 citations
  Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppress...
  Sally Hodder, Kathleen Squires, Cissy Kityo, Debbie Hagins, Anchalee Avihingsanon, Anna Kido, Shuping Jiang, Rima Kulkarni, Andrew T. A. Cheng, Huyen Cao> ;Journal of Acquired Immune Deficiency Syndromes. 2018 Jun 1
• Fixed-Dose Combination Dolutegravir, Abacavir, and Lamivudine Versus Ritonavir-Boosted Atazanavir plus Tenofovir Disoproxil Fumarate and Emtricitabine in Previously Un...
  Debbie P Hagins, Debbie P Hagins> ;The Lancet.
• 67 citations
  Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
  Kathleen Squires, Cissy Kityo, Margaret Johnson, Evgeny Voronin, Debbie Hagins, Anchalee Avihingsanon, Ellen Koenig, Shuping Jiang, Kirsten L. White, Andrew K. Cheng, ...> ;The Lancet. HIV. 2016 Sep 1
• 144 citations
  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1...
  David A. Margolis, Cynthia Brinson, Graham H R Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, Marty St. Clair, Marita Stevens, Peter Williams, ...> ;The Lancet. Infectious Diseases. 2015 Oct 1
• 47 citations
  Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients
  Josep M. Gatell, Javier O Morales-Ramirez, Debbie Hagins, Melanie A. Thompson, Arasteh Keikawus, Christian Hoffmann, Sorin Rugină, Olayemi Osiyemi, Simona Escoriu, Rob...> ;Journal of the International AIDS Society. 2014 Feb 11
• 55 citations
  Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
  Bisher Akil, Gary Blick, Debbie Hagins, Moti Ramgopal, Gary Richmond, Rafik M Samuel, Naomi Givens, Cindy Vavro, Ivy Song, Brian Wynne, Mounir Ait-Khaled> ;Antiviral Therapy. 2014 Apr 1
• Join now to see all